Key FDA Official, CBD Task Force Leader Amy Abernethy Resigns
By
Posted on
Abernethy has served the FDA since 2019
The process for regulating CBD was dealt another setback Tuesday with the resignation of Dr. Amy Abernethy, who will leave the U.S. Food and Drug Administration in mid- to late April.
Abernethy’s resignation was announced in a memo from acting FDA Commissioner Janet Woodcock.
Abernethy has served as the FDA’s principal deputy commissioner and acting chief information officer since February 2019.
She also leads the agency’s CBD Working Group, a task force formed in early 2019 to address:
- Knowledge gaps around CBD products.
- Explore potential pathways for products containing CBD to be lawfully marketed.
- The impact of CBD products on public health.
To Read The Rest Of This Article On Hemp Industry Daily, Click Here
